Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated January 23, 2014, details the completion of the initial phase of a tender offer by Jazz Pharmaceuticals Plc (Jazz) to acquire Gentium S.p.A. (Gentium). The report also discloses the amendment of Jazz's credit agreement to finance this acquisition.
Key Financial Metrics and Transaction Details
- Tender Offer Price: $57.00 per Ordinary Share and per American Depositary Share (ADS).
- Shares Accepted: 4,570,991 Ordinary Shares and 7,673,165 ADSs.
- Ownership Acquired: Approximately 79% of outstanding shares and 69% of fully diluted shares.
- Total Cost: Approximately $698 million for shares accepted as of January 22, 2014.
- Financing Structure:
- Incremental Term Loans: $350 million.
- Revolving Credit Facility: Increased to $425 million (from $200 million); $300 million utilized for the tender offer.
- Total New Term Loans: Refinanced prior term loans of approximately $554.4 million plus the new $350 million tranche.
- Interest Rates:
- New Term Loans: LIBOR + 2.50% (0.75% floor) or Prime + 1.50% (1.75% floor).
- Revolving Facility: LIBOR + 2.50% or Prime + 1.50% (subject to reduction based on leverage ratio).
- Maturity Dates: New Term Loans mature June 12, 2018; Revolving Facility matures June 12, 2017.
Material Changes and Subsequent Actions
Following the expiration of the initial offer on January 22, 2014, Jazz commenced a subsequent offering period to acquire remaining untendered shares. This period expires on February 20, 2014, at the same price of $57.00 per share. Additionally, approximately 1.35 million ADSs (9% of outstanding shares) are committed via guaranteed delivery procedures, and options for approximately 1.67 million shares are subject to support agreements requiring tender.
Outlook, Risks, and Contingencies
- Financial Covenants: The amended credit agreement requires Jazz to maintain a maximum secured leverage ratio. Mandatory prepayments of 50% of excess cash flow are required starting fiscal year 2014, potentially reducing to 25% or 0% based on leverage ratios.
- Collateral: Obligations are secured by a perfected security interest in substantially all tangible and intangible assets of the Loan Parties and 65% of the voting equity of certain subsidiaries.
- Events of Default: Include failure to make payments, covenant breaches, insolvency, change in control, and material misrepresentations.
- Forward-Looking Statements: The filing includes a Safe Harbor statement noting that actual results regarding the tender offer completion and timing may differ materially from expectations due to risks detailed in prior SEC filings.
Investor Verification Checklist
- Verify the final percentage of Gentium shares acquired after the subsequent offering period concludes on February 20, 2014.
- Review the full text of the Tender Offer Agreement (Exhibit 2.1) for specific conditions and terms.
- Examine the Amended Credit Agreement (Exhibit 10.1) for detailed covenant calculations and leverage ratio definitions.
- Monitor the filing of historical and pro forma financial statements, which are due within 71 days of this report.
- Assess the impact of the increased debt load ($350M new term loans + $300M revolver draw) on Jazz's future liquidity and interest coverage.